Back to search results

Multiparametric PET Imaging for Blood Flow and Glucose Metabolism

This study aims to improve how we measure blood flow and glucose metabolism (how your body uses sugar for energy) at the same time using a single imaging technique called PET. Researchers are testing if they can get information about blood flow from a common PET drug called 18F-FDG, which is usually only used to measure glucose metabolism. You would receive two types of PET/CT scans: one with 18F-FDG (an FDA-approved drug) and one with 11C-butanol (a drug still under investigation). This study is for healthy adults and those with cardiovascular disease, aged 18 and older. The goal is to see if 18F-FDG alone can provide both measurements, which could help doctors understand conditions like heart disease and cancer better. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 60 participants. It involves receiving two different PET/CT scans.
What's involved
You would undergo two dynamic PET/CT scans, either on the same day or within two weeks. You would also need to fast for at least 6 hours before the scan and avoid strenuous exercise for 24 hours prior.
Compensation
Not stated in the trial record.
Follow-up
Blood flow will be measured during the procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06014515

Single-tracer Multiparametric PET Imaging

Recruiting
EARLY_PHASE1Ages 18+InterventionalBasic science
University of California, Davis
~60 participants
Updated 2026-03-10 on ClinicalTrials.gov
What's tested:18F-FDG11C-butanol

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Blood Flow
Measured over during the procedure

Conditions

Healthy Subjects
Cardiovascular Disease

Explore related trials

Cardiometabolic DiseaseCardiovascular DisorderCor PulmonaleHealthy Subjects

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Guobao Wang, PhD · PRINCIPAL_INVESTIGATOR · University of California, Davis

Who to contact

Clinical Research Team
[email protected]
916-731-9004
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults (age ≥ 18 years old)
Ability to understand and willingness to sign an informed consent form
Ability to adhere to the study visit schedule and other protocol requirements.
Willing and able to fast for at least 6 hours before and for the duration of the scan
No strenuous exercise for 24 hours prior to being scanned
Willing to lie on the scanner bed for up to 60 minutes
Free of active COVID-19 symptoms
Patients with clinically acute or chronic conditions such as cardiovascular, cardiometabolic, or cardiopulmonary diseases, which may include but are not limited to ischemic heart disease, myocarditis, arrhythmias, heart failure, nonalcoholic fatty liver disease, COVID-related sequala, diabetes, hypertension, or renal disease that would result in changes in normal tissue perfusion and/or metabolism.

Exclusion

Self-reported history of dysphoria or anxiety in closed spaces
Body weight \>240 kg due to limitations of the scanner bed
Pregnant or breast-feeding (due to risks of ionizing radiation; urine pregnancy test will be administered prior to start of each PET/CT session for all participants between 18 to 60 years old who are able to get pregnant, unless documented hysterectomy or bilateral ovarian removal is available)
Blood glucose greater than 200 as assessed by fingerstick method before injection of 18F-FDG
Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.
Prisoners
Any condition that would prevent the understanding or rendering of informed consent.
Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.

What this trial measures

  • Blood Flowduring the procedure

    The primary study endpoint is to evaluate if the blood flow estimated with 18F-FDG is quantitatively equal to the blood flow measured with the flow-dedicated tracer 11C-butanol measured in ml/min/g.